Indian Journal of Animal Research

Indian Journal of Animal Research cover
Volume 59 · Issue 12 · 2025/12/20

Assessment of Anticancer Capacities of (Ceftriaxone/Zn) Drug Complex with Chemical Characterization against Three Cancer Cell Lines of Breast, Hepatic and Large Cell Lung Cancer (MCF-7; HepG-2; H460)

Jawaher J. Albaqami
110 Views

Submitted

2025/06/28

First Online

2025/12/20

doi

10.18805/IJAR.BF-2038

Cite article - Jawaher J. Albaqami. (2025). Assessment of Anticancer Capacities of (Ceftriaxone/Zn) Drug Complex with Chemical Characterization against Three Cancer Cell Lines of Breast, Hepatic and Large Cell Lung Cancer (MCF-7; HepG-2; H460). Indian Journal of Animal Research. 59(12): 2046–2053. doi: 10.18805/IJAR.BF-2038

Abstract

Background: Ceftriaxone (CF) shows high and wide range of the potent antibacterial activity with rare some side effects, a long half-life. Now new transition metal drug complex attract more attention for evolving of new capacities with multi-therapeutic approach such as anticancer activities.

Methods: CF/Zinc (CF/Zn) complex was prepared and characterized via the transmission and scanning electron microscope. CF/Zn complex was prepared in (1:1) ceftriaxone: Zn +2 ratio.

Result: (CF) coordinated as a tetradentate ligand towards zinc metal ion with the molecular formula [Zn(CF)(H 2 O) 2 ].2H 2 O.The particle size and morphological surface for zinc complex was examined by using of many analyses: SEM, EDX, TEM, TGA/DTG and X-ray diffraction. This study investigated the effect of CF/Zn metal complex as a potent anticancer agent against three cancer cell lines (Breast adenocarcinoma MCF-7, Hepatocellular carcinoma HepG-2 and large cell lung cancer H460). The synthesized complex showed great anticancer capacities against the three cell lines at conc. 10 ug/ml and the living percentages were: 95.44, 90.6 and 94.04 µg/ml respectively and inhibited the proliferation of the cancer cells at conc.100 ug/ml and the living percentages were 90.35, 80.25 and 84.26 µg/ml. Exposure to CF/Zn complex even at very low concentrations elevated anticancer capacities of CF against three dangerous and common cancer types worldwide.

References

  1. Algehani, R.A., Abou Khouzam, R., Hegazy, G.A., Alamoudi, A.A., El-Halawany, A.M., El Dine, R.S., Ajabnoor, G.A., Al-Abbasi, F.A., Baghdadi, M.A., Elsayed, I. et al . (2021). Colosso- lactone-G synergizes the anticancer properties of 5- fluorouracil and gemcitabine against colorectal cancer cells. Biomed. Pharmacother . 140: 111730. Al-Thubaiti, E.H., El-Megharbel, S.M., Albogami, B., Hamza, R.Z. (2022). Synthesis, Spectroscopic, Chemical Characteri- zations, Anticancer Capacities against HepG-2, Antibacterial and Antioxidant Activities of Cefotaxime Metal Complexes with Ca(II), Cr(III), Zn(II), Cu(II) and Se(IV). Antibiotics. 11: 967. AlZahrani, S.S., El-Megharbel, S.M., Al-Thubaiti, E.H., Alghamdi, M.A.m. Hassoubah, S.A., Qattan,S.Y.A., Alaidaroos, B.A., Albqami,N.M., AL-Harbi, M.S., Hamza, R.Z. (2025). Chemical and spectroscopic characterization of novel dexamet- hasone/zn complex as a potent antioxidant and antibacterial agent. Indian Journal of Animal Research . 59(8): 1329- 1340. doi: 10.18805/IJAR.BF-1939 . Banerjee, A., Dahiya, M., Anand, M.T., Kumar, S. (2013). Inhibition of proliferation of cervical and leukemic cancer cells by penicillin. G. Asian Pac. J. Cancer Prev . 14: 2127-2130. Banerjee, S., Booth, C.M., Bruera, E., Büchler, M.W., Drilon, A., Fry, T.J., Ghobrial, I.M., Gianni, L., Jain, R.K., Kroemer, G. et al . (2024). Two decades of advances in clinical oncology- lessons learned and future directions. Nat. Rev. Clin. Oncol. 21: 771-780. Borovskaya, T.G., Gol’dberg, E.D. (2000). Effects of anthracyclines on reproductive function in rats. bull. Exp. Biol. Med . 130: 1066-1068. Boursi, B., Haynes, K., Mamtani, R., Yang, Y.X. (2015). Impact of antibiotic exposure on the risk of colorectal cancer. Pharmacoepidemiol. Drug. Saf . 24: 534-542. Corsello, S.M., Nagari, R.T., Spangler, R.D., Rossen, J., Kocak, M., Bryan, J.G., Humeidi, R., Peck, D., Wu, X., Tang, A.A. et al . (2020). Discovering the anti-cancer potential of non- oncology drugs by systematic viability profiling. Nat. Cancer . 1: 235-248. Dahiya, D., Nigam, P.S. (2023). Antibiotic-therapy-induced gut dysbiosis affecting gut microbiota-brain axis and cognition: Restoration by intake of probiotics and synbiotics. Int. J. Mol. Sci . 24: 3074. El-Megharbel, S.M., Qahl, S.H., Alaryani, F.S., Hamza, R.Z. (2022). Synthesis, spectroscopic studies for five new mg (ii), fe (iii), cu (ii), zn (ii) and se (iv) ceftriaxone antibiotic drug complexes and their possible hepatoprotective and antioxidant capacities. Antibiotics . 11: 547. El-Megharbel, S.M., Albogami, B.,Alaidaroos, B.A., Al-Gheffari, H.K., Albaqami, N.M., Albaqami, J.J., AL-Harbi, M.S.,Hamza, R.Z. (2025). Spectroscopic analysis of copper minocycline novel complex and evaluation of its potent antibacterial, antioxidant and anti-breast cancer (mcf-7) properties. Indian Journal of Animal Research . 59(7): 1120-1130. doi: 10.18805/IJAR.BF-1948 . Gao, Y., Shang, Q., Li, W., Guo, W., Stojadinovic, A., Mannion, C., Man, Y., Chen, T. (2020). Antibiotics for cancer treatment: a double-edged sword. J. Cancer . 11: 5135-5149. Gholamhoseinian, A., Fallah, H., Sharififar, F. (2009). Inhibitory effect of methanol extract of rosa damascena mill. flowers on á-glucosidase activity and postprandial hyperglycemia in normal and diabetic rats. Phytomedicine . 16: 935-941. Global Cancer Observatory: Cancer Today (Version 1.1) (2024). Lyon, France: International Agency for Research on Cancer. Available online: https://gco.iarc.who.int/today. Gupta, S.P. (2018). Roles of metals in human health. MOJ Biorg. Org. Chem . 2: 221-224. He, X., Yao, Q., Fan, D., Duan, L., You, Y., Liang, W., Zhou, Z., Teng, S., Liang, Z., Hall, D.D. et al . (2021). Cephalosporin antibiotics specifically and selectively target nasopharyngeal carcinoma through hmox1-induced ferroptosis. Life Sci. 277: 119457. Huang, X.Z., Gao, P., Song, Y.X., Xu, Y., Sun, J.X., Chen, X.W., Zhao, J.H., Wang, Z.N. (2019). Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: A pooled analysis of 2740 cancer patients. OncoImm- unology . 8: e1665973. Kapoor, G., Saigal, S., Elongavan, A. (2017). Action and resistance mechanisms of antibiotics: A guide for clinicians. J. Anaesthesiol. Clin. Pharmacol . 33: 300-305. Karamanolis, N.N., Kounatidis, D., Vallianou, N. G., Dimitriou, K., Tsaroucha, E., Tsioulos, G., Anastasiou, I.A., Mavrothalassitis, E., Karampela, I., Dalamaga, M. (2025). Unraveling the anti- cancer mechanisms of antibiotics: Current insights, controversies and future perspectives. Antibiotics . 14(1): 9. https://doi.org/10.3390/antibiotics14010009. Kuhn, D. (2004). Beta-lactams and their potential use as novel anticancer chemotherapeutics drugs. Front. Biosci . 9: 2605. Li, X., Li, H., Li, S., Zhu, F., Kim, D.J., Xie, H., Li, Y., Nadas, J., Oi, N., Zykova, T.A. et al . (2012). Ceftriaxone, an FDA-approved cephalosporin antibiotic, suppresses lung cancer growth by targeting aurora B. Carcinogenesis . 33: 2548-2557. Lima, L.M., Silva, B.N.M.D., Barbosa, G., Barreiro, E.J. (2020). β- lactam antibiotics: An overview from a medicinal chemistry perspective. Eur. J. Med. Chem . 208: 112829. Mattiuzzi, C., Lippi, G. (2019). Current Cancer Epidemiology. J. Epidemiol. Glob. Health . 9: 217. Murugaiyan, J., Kumar, P.A., Rao, G.S., Iskandar, K., Hawser, S., Hays, J.P., Mohsen, Y., Adukkadukkam, S., Awuah, W.A., Jose, R.A.M. et al . (2022). Progress in alternative strategies to combat antimicrobial resistance: Focus on antibiotics. Antibiotics . 11: 200. Petrelli, F., Ghidini, M., Ghidini, A., Perego, G., Cabiddu, M., Khakoo, S., Oggionni, E., Abeni, C., Hahne, J.C., Tomasello, G. et al . (2019). Use of antibiotics and risk of cancer: A systematic review and meta-analysis of observational studies. Cancers . 11: 1174. Pushpakom, S., Iorio, F., Eyers, P.A., Escott, K.J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C. et al . (2019). Drug repurposing: Progress, challenges and recommen- dations. Nat. Rev. Drug Discov . 18: 41-58. Rinninella, E., Raoul, P., Cintoni, M., Franceschi, F., Miggiano, G.A.D., Gasbarrini, A., Mele, M.C. (2019). What Is the healthy gut microbiota composition? a changing ecosystem across age, environment, diet and diseases. Microorganisms . 7: 14. Sakari, M., Laisi, A., Pulliainen, A.T. (2022). Exotoxin-targeted drug modalities as antibiotic alternatives. ACS Infect. Dis . 8: 433-456. Sommer, F. anderson, J.M., Bharti, R., Raes, J., Rosenstiel, P. (2017). The resilience of the intestinal microbiota influences health and disease. Nat. Rev. Microbiol . 15: 630-638. Svensson, H.P., Vrudhula, V.M., Emswiler, J.E., MacMaster, J.F., Cosand, W.L., Senter, P.D., Wallace, P.M. (1995). In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates. Cancer Res . 55: 2357-2365. Wang, J., Chang, C., Lin, J., Wu, L., Chuang, L., Lai, M. (2014). Infection, antibiotic therapy and risk of colorectal cancer: A nationwide nested case-control study in patients with type 2 diabetes mellitus. Int. J. Cancer . 135: 956-967. Wang, L., Song, Y., Wang, H., Zhang, X., Wang, M., He, J., Li, S., Zhang, L., Li, K., Cao, L. (2023). Advances of artificial intelligence in anti-cancer drug design: A review of the past decade. Pharmaceuticals . 16: 253. Yildirim, M., Ozgeris, B., Gormez, A. (2022). substituted phenethy- lamine-based β-lactam derivatives: Antimicrobial, anticancer and β-lactamase inhibitory properties. Bioorg. Chem . 129: 106212. Yip, H.Y.K., Papa, A. (2021). Signaling pathways in cancer: therapeutic targets. combinatorial treatments and new developments. Cells. 10: 659. Zhang, H., García Rodríguez, L.A., Hernández-Díaz, S. (2008). Antibiotic use and the risk of lung cancer. cancer epidemiol. Biomark. Prev . 17: 1308-1315.
EDITORIAL BOARD

Guided by Experienced Academic Leadership

Distinguished scholars and subject experts committed to editorial excellence, scientific integrity and rigorous peer review.

View Full Board
Yashpal Singh Malik
Chief Editor

Yashpal Singh Malik

Deputy Director General (Agricultural Education)Indian Council of Agricultural Research, Headquarters, New Delhi , India

L.D. Singla
Associate chief editor

L.D. Singla

Professor and HeadAbhilashi University, Chachyot, Himachal Pradesh, India

Vilas G. Atkare
Editor

Vilas G. Atkare

DeanDr. Panjabrao Deshmukh Krishi Vidyapeeth, Akola, Krishi Nagar, Maharashtra, India

S. Maya
Editor

S. Maya

Associate Dean and Professor & HeadKerala Veterinary and Animal Sciences University, Mannuthy, Thrissur, Kerala, India